← All drugs Report issue

fn-1501

Small moleculeexperimental

Clinical trial activity

1 trials · 1 clinical orgs · 0 marketing orgs

Phase 1

1

Phase 2

0

Phase 3

0

Phase 4

0

Earliest trial started Jul 23, 2018 (NCT03690154)

Timeline

2010s

Jan 1, 2018
Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

Receptor-type tyrosine-protein kinase FLT3INHIBITOR
FLT3 inhibitor
- Receptor-type tyrosine-protein kinase FLT3 (Flt3) ↗
Vascular endothelial growth factor receptor 2INHIBITOR
KDR inhibitor
- Vascular endothelial growth factor receptor 2 (KDR) ↗
ALK tyrosine kinase receptorINHIBITOR
ALK inhibitor
- ALK tyrosine kinase receptor (ALK) ↗
Proto-oncogene tyrosine-protein kinase receptor RetINHIBITOR
RET inhibitor
- Proto-oncogene tyrosine-protein kinase receptor Ret (Ret) ↗
Platelet-derived growth factor receptor alphaINHIBITOR
PDGFRA inhibitor
- Platelet-derived growth factor receptor alpha (PDGFRA) ↗

Chemistry & pharmacology

Inorganic: No
Polymer: No

Oral

No

Parenteral

No

Topical

No

Sources

ChEMBLCHEMBL4594474 ↗

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT03690154	Phase 1	Jul 23, 2018	Fosun

Showing 1 of 1 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Fosun	For profit	1	1	1	2018

1 organizations

Page 1 / 1